Print

Purpose

The purpose of this research study is to (1) provide access to fenfluramine for patients with intractable epilepsy associated with Dravet syndrome, and (2) evaluate the safety of fenfluramine.

Condition

Eligibility

Eligible Ages
Over 2 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Criteria

Inclusion Criteria:

- Genetic diagnosis of Dravet syndrome with intractable seizures despite failing all
available medications for seizures.

Study Design

Phase
Study Type
Expanded Access

Recruiting Locations

University of California, Los Angeles
Los Angeles 5368361, California 5332921 90095-1752
Contact:
Shaun Hussain, MD
310-206-4037

More Details

Status
Available
Sponsor
University of California, Los Angeles

Study Contact

Angela Martinez
310-206-4037
angelamartinez@mednet.ucla.edu

Detailed Description

The purpose of this research study is to (1) provide access to fenfluramine for patients with intractable epilepsy associated with Dravet syndrome, and (2) evaluate the safety of fenfluramine.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.